GABPB2

GABPB2 Full Name

GA binding protein transcription factor, beta subunit 2

GABPB2 Introduction

GA binding protein transcription factor beta subunit 2 (GABPB2), also referred to as GABPβ2, is an isoform of the beta subunit of the GA-binding protein (GABP) transcription factor complex, a member of the ETS family of transcription factors. Encoded by the GABPB2 gene (also annotated as GABPB1-IT1 or a distinct GABPB1 paralog) on chromosome 1q21.3, GABPB2 shares extensive homology with GABPB1, the primary GABPβ subunit. The functional GABP complex is an obligate heterotetramer composed of two GABPα subunits (which contain the ETS DNA-binding domain) and two GABPβ subunits (which provide the transactivation domain and mediate dimerization). Together, this complex regulates the transcription of genes involved in mitochondrial biogenesis, cell cycle control, ribosomal protein expression, and neuromuscular junction formation.

Figure 1. Strcuture of GABPB2.

GABP Complex Architecture and Transcriptional Regulation
The GABP complex adopts an (α₂β₂) heterotetrameric architecture in which GABPα binds to the core DNA motif 5'-CGGAAR-3' (the ETS binding site), while GABPβ (including GABPB2) forms a dimerization interface through its N-terminal ankyrin repeats that enables cooperative binding to tandem ETS sites. GABPβ2 contains a C-terminal transactivation domain rich in glutamine and serine/threonine residues that recruits the transcriptional coactivator p300/CBP and components of the Mediator complex to activate target gene transcription. The GABP complex is a master regulator of nuclear-encoded mitochondrial genes through its control of nuclear respiratory factor 2 (NRF-2) target gene expression, coordinating mitochondrial oxidative phosphorylation capacity with cellular energy demands. GABP also directly regulates the expression of ribosomal protein and translation initiation factor genes, linking protein synthesis capacity to cellular growth signals.

GABPB2 in Myeloid Leukemogenesis and Metabolic Disorders
The GABP complex, including GABPB2, has emerged as a critical mediator of myeloid leukemogenesis. GABP is required for the maintenance of hematopoietic stem cell self-renewal capacity, and its persistent activation contributes to the pathogenesis of acute myeloid leukemia (AML) driven by oncogenic fusion proteins (e.g., RUNX1-ETO, PML-RARα). In these contexts, GABP directly activates an aberrant transcriptional program that sustains leukemic stem cell proliferation and blocks differentiation. Pharmacological disruption of GABP complex assembly, for instance using small molecules that interfere with GABPα-GABPβ heterodimerization, has shown anti-leukemic activity in preclinical models. Beyond hematopoiesis, GABPB2 may also influence metabolic disease susceptibility: GABP regulates the expression of the gene encoding deiodinase 2 (DIO2), a thyroid hormone-activating enzyme, with potential implications for energy expenditure and body weight regulation. The distinct contributions of GABPB1 versus GABPB2 isoforms to these processes await further characterization.

Alternate Names for GABPB2

GABPB2; GA binding protein transcription factor, beta subunit 2; GA-binding protein subunit beta-2; MGC29891; GABPB-2; GABP subunit beta-2; RP11-68I18.1;